Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...

During MS Awareness Month, a Groundbreaking Research-and-Care Model Looks Back on 20 Years of Firsts I am eager to see ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

The discovery could open up new ways for treating diseases such as MS by leveraging molecules that are already present in the human body. The post Gene yaks have could inspire new multiple sclerosis ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

An estimated 2.8 million people worldwide are living with multiple sclerosis (MS), according to the National MS Society.

Significantly higher levels of HRQoL were reported in patients who lived in cities, had lower MS severity and fatigue, had higher cognitive processing speed, and had achieved higher educational ...

The connection between multiple sclerosis and Epstein-Barr virus (EBV) is strengthening, according to a paper published this ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...